USPTO Notice of Allowance Marks Major Achievement for Protelica’s Series of VEGFR-2 Antibody Mimics

Staying up-to-date has never been simpler. Sign up for free job search tips!

HAYWARD, Calif., May 1, 2013 (GLOBE NEWSWIRE) -- Crowning almost eight years of research and development Protelica, Inc., an innovator in the field of protein engineering, just received a notice allowance for “UNIVERSAL FIBRONECTIN TYPE III BINDING-DOMAIN LIBRARIES” (U.S. Patent Application No. 12/820,018), a patent for composition of matter on a novel series of VEGFR-2 antagonists.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC